Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from SVB Leerink

Benzinga's Top Ratings Upgrades, Downgrades For October 21, 2022

Upgrades

Benzinga

This Is What Whales Are Betting On Moderna

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

What Are Whales Doing With Moderna

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna Whale Trades For August 23

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 53 strange trades.

Benzinga

Looking At Moderna's Recent Whale Trades

Benzinga

BioNTech Whale Trades For August 09

A whale with a lot of money to spend has taken a noticeably bullish stance on BioNTech. Looking at options history for BioNTech (NASDAQ:BNTX) we detected 10 strange trades.

Benzinga

Moderna Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 14 strange trades.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Looking At Moderna's Recent Whale Trades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 15, 2022

Benzinga

This Analyst Says US Government Buying More COVID-19 Vaccines At Higher Prices

Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced a new COVID-19 vaccine supply agreement with the U.S. government. SVB Leerink says that the new contract implies the price per Comirnaty dose is ~$30.50. Comirnaty U.S. pricing per dose has increased from $19.50 (2020 contracts), to $24 (+23%; 2021 contract), and now to ~$30.50 (+27%). The analysts…

Benzinga

What SVB Says On Axsome's Strategy Review On Sunosi For Sleeping Disorder

Axsome Therapeutics Inc (NASDAQ: AXSM) held an investor event to review its strategy with Sunosi, which is indicated for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea (OSA). SVB Leerink says its view on Sunosi has not changed.

Benzinga

Analysts Believe Madrigal's Resmetirom Shows Impressive Overall Profile In Liver Fibrosis

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) presented multiple resmetirom abstracts at the European Association for the Study of the Liver's International Liver Congress. The data included new details on changes in FibroScan controlled attenuation parameter and liver stiffness measurement along with magnetic resonance elastography, which serves as critical non-invasive measures of liver stiffness and fibrosis. …

Benzinga

Merck/Seagen Potential Deal Talks Pick Up Speed: WSJ

Merck & Co Inc (NYSE:MRK) is pushing forward with a potential deal for Seagen Inc (NASDAQ:SGEN), Wall Street Journal reported, citing people familiar with the matter. The Journal mentioned that the deal could be one of the largest takeovers of the year. The Wall Street Journal reported last week that Merck was in talks to…

Benzinga

SVB Leerink Maintains Market Perform Rating for Blueprint Medicines: Here's What You Need To Know

SVB Leerink has decided to maintain its Market Perform rating of Blueprint Medicines (NASDAQ:BPMC) and lower its price target from $82.00 to $60.00. Shares of Blueprint Medicines are trading down 8.32% over the last 24 hours, at $44.07 per share.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

5 Biotech Stocks To Watch During The Week Of June 13

Biotech stocks continued to be under pressure in the past week amid broader market weakness, precipitated by economic worries. Company-specific developments also triggered downward moves. Here's a compilation of five stocks that should be on your radar in the week of June 13: 1. Novavax

Benzinga

Analysts Cuts Price Target On This Small Cap But Remain Bullish

Chardan analyst Matthew Barcus lowered the price target on Vincerx Pharma Inc (NASDAQ:VINC) to $4 from $11 and kept a Buy rating on the shares. The company announced a strategic update to focus on its Phase Ib development of lead program VIP152 in double-hit diffuse large B-cell lymphoma and chronic lymphocytic leukemia. It also…

Benzinga

SVB Leerink Sees Over 600% Upside For This Penny Biotech Stock

SVB Leerink initiated Selecta Biosciences Inc (NASDAQ:SELB) coverage with an Outperform rating and a price target of $7. The analysts view ImmTOR's approach to mitigate ADAs as de-risked by early clinical data from SEL-212 and believe that the ability to tame the immune response bodes well for ImmTOR's clinical potential in combination with…

Benzinga

Regulatory Update On Intercept Pharma's Obeticholic Acid For NASH Delayed Again

Intercept Pharmaceuticals Inc's (NASDAQ:ICPT) pre-submission meeting to discuss the marketing application for obeticholic acid (OCA) in NASH has been moved to July (vs. June scheduling). The update follows a recent request from the FDA that topline data from the REGENERATE reanalysis be provided to the agency for review before the meeting. SVB Leerink…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

SVB Sees De-Risked Opportunity For This Newly Listed Norovirus Vaccine

SVB Leerink is initiating coverage of HilleVax Inc (NASDAQ:HLVX) shares with an Outperform rating and a $30 price target. The analyst believes the company’s potentially first-in-class infant norovirus vaccine HIL214 represents a uniquely de-risked opportunity. It estimates $625 million in risk-adjusted infant HIL214 sales in 2030E ($1 billion unadjusted). The outlook is supported by…

Investors Business Daily

How Heart Drugs Could Pump $10 Billion Into Merck's Coffers

Merck stock has reinvigorated on the company's plans in heart disease. Will its efforts be enough as Keytruda goes off patent?

Benzinga

Merck & Co Whale Trades For May 18

Someone with a lot of money to spend has taken a bearish stance on Merck & Co (NYSE:MRK). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

SVB Leerink Maintains Outperform Rating for Olink Holding: Here's What You Need To Know

SVB Leerink has decided to maintain its Outperform rating of Olink Holding (NASDAQ:OLK) and lower its price target from $25.00 to $20.00. Shares of Olink Holding are trading up 5.12% over the last 24 hours, at $11.50 per share.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022

Upgrades

Benzinga

SVB Leerink Maintains Outperform Rating for Zimmer Biomet Holdings: Here's What You Need To Know

SVB Leerink has decided to maintain its Outperform rating of Zimmer Biomet Holdings (NYSE:ZBH) and raise its price target from $135.00 to $140.00. Shares of Zimmer Biomet Holdings are trading up 0.82% over the last 24 hours, at $121.67 per share.

Benzinga

Why Are Accolade Shares Down Over 40% Today

Accolade Inc (NASDAQ:ACCD) shares plunged almost 50% after disappointing Q4 FY22 earnings and FY23 guidance. Q4 FY22 revenue increased 58% Y/Y to $93.8 million, beating the consensus of $91.57 million. The company reported a wider net loss of $(34.56) million compared to $(4.73) million a year ago. EPS loss came at $(0.51)…

1 2

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.